ENZN
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.84 | $87M | -$25M |
| 2025 Q4 | -2.16 | $0 | -$682,000 |
| 2025 Q3 | -1.83 | $0 | -$1M |
| 2025 Q2 | -2.05 | $0 | -$672,000 |
| 2025 Q1 | -1.42 | $0 | -$618,000 |
| 2024 Q4 | 0.33 | $0 | $226,000 |
| 2024 Q3 | -0.37 | $0 | $404,000 |
| 2024 Q2 | -0.34 | $26,000 | $241,000 |